Get the Stockscreener App
6.46
0.15%
-0.010
After Hours:
6.78
0.32
+4.95%
Polaryx Therapeutics Inc stock is traded at $6.46, with a volume of 86,233.
It is down -0.15% in the last 24 hours and up +1.57% over the past month.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
See More
Previous Close:
$6.47
Open:
$6.35
24h Volume:
86,233
Relative Volume:
0.05
Market Cap:
$305.84M
Revenue:
-
Net Income/Loss:
$-8.99M
P/E Ratio:
-34.04
EPS:
-0.1898
Net Cash Flow:
$-3.94M
1W Performance:
+12.54%
1M Performance:
+1.57%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.34
$7.10
1-Week Range:
$5.26
$7.10
52-Week Range:
$2.201
$33.90
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Name
Polaryx Therapeutics Inc
Sector
Industry
Phone
201-940-7236
Address
140 EAST RIDGEWOOD AVENUE, PARAMUS
Compare PLYX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLYX
Polaryx Therapeutics Inc
|
6.46 | 306.31M | 0 | -8.99M | -3.94M | -0.1898 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Initiated | Maxim Group | Buy |
Polaryx Therapeutics Inc Stock (PLYX) Latest News
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care - The Manila Times
A rare-disease biotech, Polaryx, just won a pediatric care award - Stock Titan
Number of employees of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView — Track All Markets
PLYX Technical Analysis | Trend, Signals & Chart Patterns | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill
PLYX Stock Price and Chart — NASDAQ:PLYX - TradingView — Track All Markets
Polaryx Therapeutics, Inc.Common Stock (NQ: PLYX - The Chronicle-Journal
Polaryx Therapeutics, Inc. News — NASDAQ:PLYX - TradingView — Track All Markets
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Polaryx Therapeutics, Inc. (PLYX) stock price, news, quote and history - Yahoo Finance UK
PLYX: Polaryx Therapeutics, Inc.Options Chain - Zacks Investment Research
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference - Bitget
Polaryx to webcast Needham healthcare presentation on Apr. 16 - Stock Titan
Polaryx Therapeutics Inc (NASDAQ: PLYX)Share Price - intelligentinvestor.com.au
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Harmony Biosciences stock faces pipeline scrutiny amid Polaryx integration challenges and rare disea - AD HOC NEWS
Polaryx Therapeutics: Advancing Innovative Therapies for Rare Pediatric Lysosomal Storage Disorders (LSDs) - Minichart
Polaryx Therapeutics (NASDAQ: PLYX) outlines rare pediatric LSD pipeline - Stock Titan
PLYX: Net loss improved to $9.0M in 2025, but cash only funds operations through Q3 2026 - TradingView
Polaryx Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Polaryx Therapeutics, Inc.(NasdaqCM: PLYX) added to S&P TMI Index - marketscreener.com
Polaryx Therapeutics (PLYX) Stock Trends and Sentiment 2026 - MarketBeat
FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease By Investing.com - Investing.com South Africa
Polaryx Therapeutics (PLYX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Polaryx’s PLX-200 granted FDA Fast Track Designation in LINCL/CLN2 - tipranks.com
FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease - Investing.com
Polaryx Therapeutics Says FDA Grants Fast Track Status to PLX-200 - marketscreener.com
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) - The Manila Times
FDA Fast Track for PLX‑200 targeting rare pediatric disorder - Stock Titan
Should I buy Polaryx Therapeutics, Inc. (PLYX) - Zacks Investment Research
Polaryx Therapeutics Stock Rises Amidst Key Clinical Trials Development - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
Top Polaryx Therapeutics (PLYX) Competitors 2026 - MarketBeat
Polaryx Therapeutics Stock Surges With New Phase Trial Decision - StocksToTrade
PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events - Bitget
Biotech backs Krabbe families with research summit and Putt-Putt event - Stock Titan
Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? - Asianet Newsable
Polaryx Therapeutics (PLYX) Insider Trading Activity 2026 - MarketBeat
PLYX Forecast, Price Target & Analyst Ratings | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill
Polaryx Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PLYX | US73110F1003 - marketscreener.com
Polaryx commits to patients with rare pediatric lysosomal storage disorders - TipRanks
Polaryx Therapeutics Inc (PLYX) Stock Price, Quote, News & History - Benzinga
Maxim starts Polaryx at Buy, sees PLX-200 as differentiated - TipRanks
PLYX | Polaryx Therapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders - Bitget
Polaryx Therapeutics Inc Stock (PLYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):